BIGG

A living WHO guideline on drugs to prevent COVID-19

Lamontagne, François; Agoritsas, Thomas; Siemieniuk, Reed; Rochwerg, Bram; Bartoszko, Jessica; Askie, Lisa; Macdonald, Helen; Amin, Wagdy; Bausch, Frederique Jacquerioz; Burhan, Erlina; Cecconi, Maurizio; chanda, Duncan; Quoc Dat, Vu; Du, Bin; Geduld, Heike; Gee, Patrick; Nerina, Harley; Hashimi, Madiha; Hunt, Beverley; Kabra, Sushil; Kanda, Seema; Kawano-Dourado, Leticia; Kim, Yae-Jean; Kissoon, Niranjan; Kwizera, Arthur; Leo, Yee-Sin; Mahaka, Imelda; Manai, Hela; Mino, Greta; Nsutebu, Emmanuel; Pshenichnaya, Natalia; Qadir, Nida; Ranganathan, Shalini Sri; Sabzwari, Saniya; Sarin, Rohit; Sharland, Michael; Shen, Yinzhong; Souza, Joao; Stegemman, Miriam; Ugarte, Sebastian; Venkatapuram, Sridhar; Vuyiseka, Dubula; Preller, Jacobus; Brignardello-Petersen, Romina; Kum, Elena; Qasim, Lyubov; Zeraatkar, Dena; Owen, Andrew; Guyatt, Gordon; Lytvyn, Lyubov; Diaz, Janet; Vandvik, Per; Jacobs, Michael.

BMJ (Online); 372 (526), 2021

Clinical question What is the role of drugs in preventing covid-19? Why does this matter?There is widespread interest in whether drug interventions can be used for the prevention of covid-19, but there is uncertainty about which drugs, if any, are effective. The first version of this living guideline foc...

COVID-19/tratamiento farmacológico, SARS-CoV-2/efectos de los fármacos, Hidroxicloroquina/uso terapéutico

Texto completo

Remdesivir for severe COVID-19: a clinical practice guideline

BMJ; 370 (), 2020

Clinical question: What is the role of remdesivir in the treatment of severe covid-19? This guideline was triggered by the ACTT-1 trial published in the New England Journal of Medicine on 22 May 2020.Remdesivir has received worldwide attention as a potentially effective treatment for severe covid-19. Aft...

Betacoronavirus, Infecciones por Coronavirus/tratamiento farmacológico, Neumonía Viral/tratamiento farmacológico, Pandemias, Ensayos Clínicos Controlados Aleatorios como Asunto, Antivirales/uso terapéutico, Resultado del Tratamiento, Índice de Severidad de la Enfermedad

Texto completo

A living WHO guideline on drugs for COVID-19

Rochwerg, Bram; Agoritsas, Thomas; Lamontagne, François; Leo, Yee-Sin; Macdonald, Helen; Agarwal, Arnav; Zeng, Linan; Lytvyn, Lyubov; Appiah, John Adabie; Amin, Wagdy; Arabi, Yaseen; Blumberg, Lucille; Burhan, Erlina; Bausch, Frederique; Calfee, Carolyn S; Cao, Bin; Cecconi, Maurizio; Chanda, Duncan; Cooke, Graham; Du, Bin; Dunning, Jake; Geduld, Heike; Gee, Patrick; Hashimi, Madiha; Hui, David S; Kabra, Sushil; Kanda, Seema; Kawano-Dourado, Leticia; Kim, Yae-Jean; Kissoon, Niranjan; Kwizera, Arthur; Laake, Jon Henrik; Machado, Flavia R; Mahaka, Imelda; Manai, Hela; Mino, Greta; Nsutebu, Emmanuel; Pshenichnaya, Natalia; Qadir, Nida; Sabzwari, Saniya; Sarin, Rohit; Sharland, Michael; Shen, Yinzhong; Ranganathan, Shalini Sri; Souza, Joao; Ugarte, Sebastian; Venkatapuram, Sridhar; Dat, Vu Quoc; Vuyiseka, Dubula; Wijewickrama, Ananda; Maguire, Brittany; Zeraatkar, Dena; Bartoszko, Jessica; Ge, Long; Brignardello-Petersen, Romina; Siemieniuk, Reed; Guyatt, Gordon; Diaz, Janet; Jacobs, Michael; Vandvik, Per Olav.

BMJ; 370 (), 2020

What is the role of drug interventions in the treatment of patients with covid-19? The latest version of this WHO living guidance focuses on remdesivir, following the 15 October 2020 preprint publication of results from the WHO SOLIDARITY trial. It contains a weak or conditional recommendation against th...

Ivermectina/uso terapéutico, Índice de Severidad de la Enfermedad, COVID-19/tratamiento farmacológico, Factores Inmunológicos/uso terapéutico, Antirretrovirales/uso terapéutico, Corticoesteroides/uso terapéutico, Hidroxicloroquina/uso terapéutico, Lopinavir/uso terapéutico

Texto completo